Phase 2
N=6
Butyrate Adjuvant Therapy for Type 1 Diabetes
Type1diabetes
Bottom Line
View on ClinicalTrials.gov: NCT03999853 ↗Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Insulin Sensitivity — 5.71; 6.02 mg/kg/min
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- BKR-017 (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Apr 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Insulin Sensitivity |
5.71; 6.02 | — |
| SECONDARY Glucose Variability |
7.1; 6.8 | — |
| SECONDARY Change in Triglycerides |
83.5; 85.2 | — |
Summary
The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with T1D and under the care of a healthcare professional for its management
- HbA1c 6.4-8.9%, inclusive
- Has given written informed consent to participate in this study
- Willing to complete 28-day baseline period and 48 -day test period
- Willing to maintain current diet and exercise routine for the duration of the study
- Current use of a Dexcom Continuous Glucose Monitor (CGM)
Exclusion Criteria
- History of bariatric or intestinal surgery
- Active gastrointestinal disease including but not limited to irritable bowel syndrome, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), diverticulitis, gastroparesis, or chronic/frequent diarrhea or chronic/frequent constipation
- Active and clinically significant hepatic, pancreatic disease, or renal disease as determined by the investigator
- History of significant heart disease, including congestive heart failure, prior MI, chronic atrial or ventricular fibrillation, coronary artery disease, cerebral vascular disease, or other cardiovascular disease, that in the opinion of the investigator should exclude the subject from the study
- Severely uncontrolled hypertension at screening defined as a systolic blood pressure > 180 mmHg or a diastolic blood pressure > 110 mmHg on the average of two seated measurements after being at rest for at least 5 minutes
- Uncontrolled hyperthyroidism or hypothyroidism, or other significant thyroid disease
- Active significant infection as determined by the investigator
- Known allergy to butyrate or any of the components of the tablets
- Participation in a clinical trial and/or treatment with an investigational drug during the 30 days before screening, or within 5 half-lives of receipt of an investigational drug or twice the duration of the biological effect of any investigational drug (whichever is longer)
- Pregnant, nursing, or trying to become pregnant
- Presence of pitting edema on physical exam
- High fiber diet
- In the investigator's judgment, the subject is not suitable for the study for any other reason or cannot commit to the requirements of the study.
- Subject is taking one or more of the excluded therapies.
Data sourced from ClinicalTrials.gov (NCT03999853). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.